---
title: US FDA CDER Reveals Why Most eCTD v4 Submissions Fail (And How to Fix Them) | EXTEDO
description: Learn why most eCTD v4 submissions fail according to the US FDA. Discover common errors and effective strategies for successful regulatory compliance.
---
[myEXTEDO Login](https://extedo.my.site.com/customersupport)[Careers](https://www.extedo.com/company/careers)
Contact Us
Software
[EXTEDOpulse Overview](https://www.extedo.com/software/extedopulse)
[Document Management Hub](https://www.extedo.com/software/document-management-hub)
[DMS Regulatory](https://www.extedo.com/software/document-management-hub/edocsmanager/edocsmanager-regulatory-module)
[eCTDtemplates](https://www.extedo.com/software/document-management-hub/eCTDtemplates)
[Registration Management Hub](https://www.extedo.com/software/registration-management-hub)
[Submission Management Hub](https://www.extedo.com/software/ectd-submission-management-publishing-software)
[Submission Publishing](https://www.extedo.com/software/ectd-submission-management-publishing-software/ectdmanager)
[Submission Viewing](https://www.extedo.com/software/esubmanager)
[Submission Reviewing](https://www.extedo.com/submission-viewing-and-reviewing/eurs)
[Submission Validation](https://www.extedo.com/software/submission-validation/eursvalidator)
[Safety Management Hub](https://www.extedo.com/software/pharmacovigilance-and-drug-safety)
[Quality Management Hub](https://www.extedo.com/software/quality-management-hub)
Services
[Regulatory Publishing Services](https://www.extedo.com/services/regulatory-publishing-services)
[Business Process and Regulatory Consulting](https://www.extedo.com/services/business-process-and-regulatory-consulting)
[Pharmacovigilance](https://www.extedo.com/services/business-process-and-regulatory-consulting/pharmacovigilance)
[eCTD Services](https://www.extedo.com/services/business-process-and-regulatory-consulting/ectd-services)
[EURS Services](https://www.extedo.com/services/business-process-and-regulatory-consulting/eurs-services)
[IDMP Services](https://www.extedo.com/services/business-process-and-regulatory-consulting/idmp)
[Technical Consulting](https://www.extedo.com/services/technical-consulting)
[Education and Training](https://www.extedo.com/services/education-and-training)
[Validation Services](https://www.extedo.com/services/installation-and-validation-services)
[Extended Support Services](https://www.extedo.com/services/extended-support-services)
[Agency](https://www.extedo.com/agency)
[Support](https://www.extedo.com/support)
[Blog](https://www.extedo.com/blog)
[Events](https://www.extedo.com/events)
[Resources](https://www.extedo.com/resources)
Company
[About EXTEDO](https://www.extedo.com/company/about)
[Locations and Contact](https://www.extedo.com/company/locations-and-contact)
[Careers](https://www.extedo.com/company/careers)
[EXTEDO Partners](https://www.extedo.com/company/extedo-partners)
[Subscribe for EXTEDO Mailings](https://www.extedo.com/company/subscribe)
# US FDA CDER Reveals Why Most eCTD v4 Submissions Fail (And How to Fix Them)
## US FDA CDER Publishes Top Reasons for eCTD v4 Rejection
Recent data released by the US FDA’s Center for Drug Evaluation and Research (CDER) highlights ongoing quality challenges in electronic Common Technical Document (eCTD) submissions, both in the legacy v3.2.2 format and the newer eCTD v4 standard.
## ** eCTD v4: High Error Rate in Early Adoption**
Between January 1 and December 31, 2025, CDER reviewed **39 eCTD v4 submissions**.
**74% contained errors**, putting them at high risk for regulatory rejection. The most frequent issues include:
- Sequence mismatches (missing, multiple, or incorrect entries)
- Duplicate sequence numbers
- Missing or incorrect information
### **Comparison with eCTD v3.2.2**
In the same period, **361,629 eCTD v3.2.2 submissions** were received. While the error rate was far lower (**1.7%**), the large volume still produced significant numbers of problematic filings:
- Duplicate sequence numbers: **1,841** cases in eCTD v3.2.2 vs. **2** in eCTD v4
- Missing fillable forms: **201** cases in eCTD v3.2.2 vs. **4** in eCTD v4
## What this means for Applicants
The data suggests that many eCTD v4 errors mirror those seen in v3.2.2 submissions, indicating that **applicant accuracy and process clarity** remain critical factors. While eCTD v4 adoption is still in its early stages, these findings underline the importance of early validation and thorough internal review before submission.
## **Recommendations for Applicants:**
- Review sequence numbers carefully to avoid gaps or duplicates
- Apply validation tools early in the process
- Verify backbone files and fillable forms for completeness
- Update submission SOPs and train staff on eCTD v4 requirements
If you would like to avoid costly FDA rejections and keep your timelines on track, contact our [Regulatory Publishing Services.](https://www.extedo.com/services/regulatory-publishing-services) They combine deep eCTD v4 expertise with meticulous quality control. Our publishing experts are based in the US and in Europe, where they...
- Prepare and validate your sequences to ensure US FDA compliance
- Check backbone files and metadata for accuracy
- Handle formatting, technical validation, and issue resolution before submission
- Provide clear communication and support throughout the process
With our help, your eCTD v4 submissions are error-free, compliant, and ready for FDA review, so you can focus on getting your product approved, not fixing mistakes.
Would you like to learn more about the latest regulatory developments in the US and Canada? Subscribe to our free monthly expert newsletter: [Regulatory Newsletter USA/Canada- Subscribe | EXTEDO](https://www.extedo.com/regulatory-newsletter-usa-canada-subscribe?)
## Latest Blog Posts
 
Why Can’t We View eCTD v4 Dossiers in a Browser? – Understanding the Technical Shift
[Read more **](https://www.extedo.com/blog/why-cant-we-view-ectd-v4-dossiers-in-a-browser-understanding-the-technical-shift)
.png?width=64&height=64&name=Introduction%20of%20ePI%20(1).png) .png?width=500&height=500&name=Introduction%20of%20ePI%20(1).png)
Introduction of ePI – The Future of Medicines Information
[Read more **](https://www.extedo.com/blog/introduction-of-epi-the-future-of-medicines-information)
 
Egyptian Drug Authority and EXTEDO Launch Phase II of Egypt’s Pharmaceutical Digital Transformation
[Read more **](https://www.extedo.com/blog/egyptian-drug-authority-and-extedo-launch-phase-ii-of-egypts-pharmaceutical-digital-transformation)
%20Your%20Essential%20Guide%20for%20Planning%20(thumb).png?width=64&height=64&name=Upcoming%20Events%20at%20the%20European%20Medicines%20Agency%20(EMA)%20Your%20Essential%20Guide%20for%20Planning%20(thumb).png) %20Your%20Essential%20Guide%20for%20Planning%20(thumb).png?width=500&height=500&name=Upcoming%20Events%20at%20the%20European%20Medicines%20Agency%20(EMA)%20Your%20Essential%20Guide%20for%20Planning%20(thumb).png)
EMA PMS Info Day 2026: The Future of Data-Driven Medicines Regulation in Europe
[Read more **](https://www.extedo.com/blog/ema-pms-info-day-2026-the-future-of-data-driven-medicines-regulation-in-europe)
[See more blog posts](https://www.extedo.com/blog)
**
## Schedule a Call
**
**
EXTEDO makes pharmaceutical compliance an effortless process. We provide solutions and expert knowledge that help life science organizations worldwide to reduce the time and effort required to create and submit regulatory applications for medicinal products and maintain them throughout their lifecycle.
EXTEDO Germany: [+49 89 189454-0](tel:+4989189454-0)
EXTEDO US: [+1 (855) 328-3500](tel:+18553283500)
- [Home](https://www.extedo.com)
- [Software](https://www.extedo.com/software/extedopulse)
- [Services](https://www.extedo.com/services/business-process-and-regulatory-consulting)
- [Support](https://www.extedo.com/support)
- [Blog](https://www.extedo.com/blog)
- [Resources](https://www.extedo.com/resources)
- [Glossary](https://www.extedo.com/glossary-of-regulatory-abbreviations)
- [Contact us](https://www.extedo.com/company/locations-and-contact)
[**](https://www.linkedin.com/company/extedo/) [**](https://www.youtube.com/user/EXTEDOsuite)
Copyright © 2026 EXTEDO. All rights reserved.
[Impressum](https://www.extedo.com/footer0/impressum)[Legal Disclaimer](https://www.extedo.com/footer0/legal-disclaimer)[Privacy Policy](https://www.extedo.com/footer0/privacy-policy)
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "EXTEDO",
"url" : "https://www.extedo.com/blog/author/extedo"
},
"dateModified" : "2026-07-21T10:12:36.448Z",
"datePublished" : "2026-06-09T12:24:04.000Z",
"headline" : "US FDA CDER Reveals Why Most eCTD v4 Submissions Fail (And How to Fix Them)",
"mainEntityOfPage" : {
"@id" : "https://www.extedo.com/blog/us-fda-cder-reveals-why-most-ectd-v4-submissions-fail-and-how-to-fix-them",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://www.extedo.com/hubfs/logo.png"
},
"name" : "EXTEDO GmbH"
}
}
```